“A metastatic hormone receptor–positive breast cancer, usually resistant to immunotherapy, is successfully treated with tumor-infiltrating lymphocytes enriched for neoantigen reactivity, underscoring the broad potential of this immunotherapeutic approach.”
.
L.G.Radvanyi
Targeting the cancer mutanome of breast cancer
Nature Medicine — Volume 27 #6 — June 2018 — page 703